Netupitant information

Netupitant
Clinical data
License data	EU EMA: by INN;
Drug class	NK1 receptor antagonists, antiemetics
ATC code	None;
Pharmacokinetic data
Bioavailability	>60% (estimated)
Protein binding	>99%
Metabolism	mainly CYP3A4; also CYP2D6 and CYP2C9
Elimination half-life	88 hours
Excretion	71% (faeces)
Identifiers
	IUPAC name 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide;
CAS Number	290297-26-6;
PubChem CID	6451149;
DrugBank	DB09048;
ChemSpider	4953629;
UNII	7732P08TIR;
KEGG	D05152;
ChEBI	CHEBI:85155;
ChEMBL	ChEMBL206253;
CompTox Dashboard (EPA)	DTXSID50183271 ;
Chemical and physical data
Formula	C30H32F6N4O
Molar mass	578.603 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccccc1c2cc(ncc2N(C)C(=O)C(C)(C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C;
	InChI InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3; Key:WAXQNWCZJDTGBU-UHFFFAOYSA-N;

Netupitant is an antiemetic medication. In the United States, the combinations of netupitant/palonosetron and the prodrug fosnetupitant/palonosetron (both brand name Akynzeo) are approved by the Food and Drug Administration for the prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin.^[1]^[2] In the European Union, the combinations are approved by the European Medicines Agency (EMA) for the same indication.^[3]^[4]

^ "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. U.S. National Library of Medicine. 30 April 2018. Archived from the original on 18 October 2020. Retrieved 19 March 2020.
^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy" (Press release). Food and Drug Administration. October 10, 2014. Archived from the original on February 1, 2017. Retrieved December 16, 2019.
^ "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 26 June 2016. Retrieved 12 July 2016.
^ "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.

[Akynzeo_FDA_label-1] "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. U.S. National Library of Medicine. 30 April 2018. Archived from the original on 18 October 2020. Retrieved 19 March 2020.

[2] "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy" (Press release). Food and Drug Administration. October 10, 2014. Archived from the original on February 1, 2017. Retrieved December 16, 2019.

[EPAR-3] "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 26 June 2016. Retrieved 12 July 2016.

[Akynzeo_EPAR-4] "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.

Netupitant information

and 27 Related for: Netupitant information

Netupitant

Fosnetupitant

Roche

Palonosetron

Maropitant

Metopimazine

Substance P

NK1 receptor antagonist

Elinzanetant

Fosaprepitant

Fezolinetant

Aprepitant

Tradipitant

Tachykinin receptor 1

Neurokinin B

Vofopitant

Rolapitant

Saredutant

Neurokinin A

Osanetant

Nepadutant

Vestipitant

Ezlopitant

Casopitant

Pavinetant

Lanepitant

Tachykinin receptor 3

Clinical data

License data	EU EMA: by INN
Drug class	NK1 receptor antagonists, antiemetics
ATC code	None
Pharmacokinetic data
Bioavailability	>60% (estimated)
Protein binding	>99%
Metabolism	mainly CYP3A4; also CYP2D6 and CYP2C9
Elimination half-life	88 hours
Excretion	71% (faeces)
Identifiers
IUPAC name 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide
CAS Number	290297-26-6
PubChem CID	6451149
DrugBank	DB09048
ChemSpider	4953629
UNII	7732P08TIR
KEGG	D05152
ChEBI	CHEBI:85155
ChEMBL	ChEMBL206253
CompTox Dashboard (EPA)	DTXSID50183271
Chemical and physical data
Formula	C₃₀H₃₂F₆N₄O
Molar mass	578.603 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Cc1ccccc1c2cc(ncc2N(C)C(=O)C(C)(C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
InChI InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3 Key:WAXQNWCZJDTGBU-UHFFFAOYSA-N